Healthcare

Popular Topics in Healthcare

Subscribe to Updates in Healthcare

By RSS

The Expertise Imperative and Compliance Technology: Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.

Learn more about GLG's Compliance Framework

This page may include content provided by Council Members, your access to which is subject to the Terms of Use.

Find Out More

December 13, 2007

Reloxin Gives Allergan's Botox A Run for the Money!

Analysis of: Ipsen and Medicis announce submission of Reloxin(R) in aesthetics to the FDA | www.pipelinereview.com

This analysis is solely the work of the author. It has not been edited or endorsed by GLG.

Analysis By:

Kenneth Edelson
Owner, Kenneth Edelson, MD

Implications: For too long Allergan has monopolized the therapeutic and cosmetic market of botulinum toxin type A, and has taken full advantage of that monopoly by raising the price of Botox almost biannually. Reloxin studies are very favorable when compared to Botox, and may even surpass it in one or two aspects. There is a lesser protein load and therefore less antigenic than Botox and this may lead to a longer lasting effect. Studies already show and support this. In addition, there is a greater diffusion of the toxin from pontiff injection, and this is desirable in certain areas as the large frontalis areas of the face, and certainly in the large areas we tret for hyperhidrosis of the palms, soles and axillae, The conversion rate of units is not to be looked at as a chore of conversion, but as learning a new language. Don't look to convert units to units...just learn the required units of the new toxin. The shelf life appears to be slily longer as well. Cudos to Reloxin-watch out Botox!

Analysis:

For too long Allergan has monopolized the therapeutic and cosmetic market of botulinum toxin type A, and has taken full advantage of that monopoly by raising the price of Botox almost biannually.
Reloxin studies are very favorable when compared to Botox, and may even surpass it in one or two aspects. There is a lesser protein load and therefore less antigenic than Botox and this may lead to a longer lasting effect. Studies already show and support this. In addition, there is a greater diffusion of the toxin from pontiff injection, and this is desirable in certain areas as the large frontalis areas of the face, and certainly in the large areas we tret for hyperhidrosis of the palms, soles and axillae, The conversion rate of units is not to be looked at as a chore of conversion, but as learning a new language. Don't look to convert units to units...just learn the required units of the new toxin.
The shelf life appears to be slily longer as well. Cudos to Reloxin-watch out Botox!

Other Analyses of the Same Source Article: